Building a brighter future for children: How will large pediatric trial networks help to deliver safe, effective medicines?
The Innovative Medicines Initiative (IMI) – Europe’s partnership for health

**IMI1: 2008-2013**
€2 bn ($2.4 bn)
59 projects

**IMI2: 2014-2020**
€3.3 bn ($4 bn)
More ambitious
More open
Greater scope

> €5 bn ($6 bn)

Partnership 2008 - 2020

€2.5 bn

BIO 2019 • IT STARTS WITH ONE
IMI – Ecosystem for innovative collaborations

IMI is a neutral platform where all involved in drug development can engage in open collaboration on shared challenges in areas of unmet medical needs.

All partners needed to find transformative solutions to reduce late stage attrition, speed patient access and improve health outcomes and find solutions for a sustainable healthcare system.

Over 11,500 researchers from an international, cross-sector community

Regulators
HTA bodies
Payers
Healthcare practitioners
Academia
Charities
SMEs
Pharma companies
Diagnostic companies
Other sectors (e.g. imaging, digital, medtech, ...)
Public health bodies
Patients

BIO 2019 • IT STARTS WITH ONE
Our panellists

Dr. Gerri Baer  
Medical Officer, Neonatology Team Leader, Office of Pediatric Therapeutics, U.S. Food and Drug Administration

Dr. Sam Maldonado  
Vice President, Head of Child Health Innovation and Leadership Department (CHILD), Johnson & Johnson

Dr. Annette Bakker  
President, Children’s Tumor Foundation